LMR Partners’s Aegerion Pharmaceuticals AEGR Stock Holding History

LMR Partners’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-25,968	Closed	-$39K	–	572
2016 Q2	$39K	Buy	+25,968	New	+$59.4K	0.01%	452

Other funds holding AEGR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

LMR Partners's AEGR Position: Q3 2016 in Review

LMR Partners sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2016, closing a stake of 25,968 shares — an estimated $39K sold.

LMR Partners first reported a position in AEGR in Q2 2016 and held it in 1 quarter. The position peaked at $39K in Q2 2016. 58 funds tracked by Wall St. Rank hold AEGR as of Q3 2016.

LMR Partners reported no remaining Aegerion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
LMR Partners sold 25,968 Aegerion Pharmaceuticals shares in Q3 2016, an estimated $39K.
LMR Partners first reported a position in Aegerion Pharmaceuticals in Q2 2016 and held it in 1 quarter.
LMR Partners's Aegerion Pharmaceuticals position peaked at $39K in Q2 2016.
58 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2016.

Based on LMR Partners's 13F filing for Q3 2016, filed 1 Nov 2016.